Duloxetine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Stress Incontinence
Conditions
Urinary Stress Incontinence
Trial Timeline
Jan 1, 2005 → Sep 1, 2006
NCT ID
NCT00190853About Duloxetine
Duloxetine is a phase 3 stage product being developed by Eli Lilly for Urinary Stress Incontinence. The current trial status is completed. This product is registered under clinical trial identifier NCT00190853. Target conditions include Urinary Stress Incontinence.
What happened to similar drugs?
20 of 20 similar drugs in Urinary Stress Incontinence were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01391221 | Approved | UNKNOWN |
| NCT01363284 | Pre-clinical | Completed |
| NCT01089621 | Approved | Withdrawn |
| NCT01051466 | Approved | Completed |
| NCT00989157 | Phase 3 | Completed |
| NCT01074151 | Pre-clinical | Completed |
| NCT00889369 | Approved | UNKNOWN |
| NCT01754493 | Approved | Completed |
| NCT01028352 | Pre-clinical | Completed |
| NCT00696774 | Approved | Completed |
| NCT00532480 | Approved | Completed |
| NCT00529789 | Phase 2 | Completed |
| NCT00696293 | Approved | Completed |
| NCT00517985 | Approved | Completed |
| NCT00398632 | Approved | Terminated |
| NCT00401258 | Approved | Completed |
| NCT00438971 | Approved | Completed |
| NCT00531895 | Approved | Completed |
| NCT00322621 | Approved | Completed |
| NCT01035073 | Approved | Completed |
Competing Products
20 competing products in Urinary Stress Incontinence